Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99


Assessment of the AQUIOS flow cytometer - An automated sample preparation system for CD4 lymphocyte PanLeucogating enumeration.

Rhodes D, Carcelain G, Keeney M, Parizot C, Benjamins D, Genesta L, Zhang J, Rohrbach J, Lawrie D, Glencross DK.

Afr J Lab Med. 2019 Dec 5;8(1):804. doi: 10.4102/ajlm.v8i1.804. eCollection 2019.


A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis.

Marcy O, Borand L, Ung V, Msellati P, Tejiokem M, Huu KT, Do Chau V, Ngoc Tran D, Ateba-Ndongo F, Tetang-Ndiang S, Nacro B, Sanogo B, Neou L, Goyet S, Dim B, Pean P, Quillet C, Fournier I, Berteloot L, Carcelain G, Godreuil S, Blanche S, Delacourt C; ANRS 12229 PAANTHER 01 STUDY GROUP.

Pediatrics. 2019 Sep;144(3). pii: e20182065. doi: 10.1542/peds.2018-2065.


Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy.

Freund R, Granger B, Francois C, Carcelain G, Ravaud P, Mariette X, Fautrel B.

Presse Med. 2018 Feb;47(2):e9-e13. doi: 10.1016/j.lpm.2017.09.029. Epub 2018 Feb 23.


What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM.

Bendenoun M, Samri A, Avettand-Fènoël V, Cardinaud S, Descours B, Carcelain G, Mazeron MC, Bergmann JF, Urrutia A, Moris A, Rouzioux C, Simon F, Andre P, Pocard M, Dray X, Mourez T, Vieillard V, Autran B, Barin F, Sellier P.

EBioMedicine. 2018 Jan;27:51-60. doi: 10.1016/j.ebiom.2017.12.003. Epub 2017 Dec 7.


Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation.

Yong MK, Cameron PU, Slavin M, Morrissey CO, Bergin K, Spencer A, Ritchie D, Cheng AC, Samri A, Carcelain G, Autran B, Lewin SR.

J Infect Dis. 2017 Jun 1;215(11):1684-1694. doi: 10.1093/infdis/jix192.


iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease.

Sbihi Z, Dossier A, Boutboul D, Galicier L, Parizot C, Emarre A, Hoareau B, Dupin N, Marcelin AG, Oudin A, Fieschi C, Agbalika F, Autran B, Oksenhendler E, Carcelain G.

Blood. 2017 Feb 16;129(7):855-865. doi: 10.1182/blood-2016-06-719716. Epub 2016 Nov 9.


Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.

Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutolleau D, Agher R, Valantin MA, Tubiana R, Calvez V, Marcelin AG, Carcelain G, Autran B, Costagliola D, Katlama C.

Clin Infect Dis. 2016 May 15;62(10):1297-1303. doi: 10.1093/cid/ciw076. Epub 2016 Feb 14.


Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.

Calin R, Hamimi C, Lambert-Niclot S, Carcelain G, Bellet J, Assoumou L, Tubiana R, Calvez V, Dudoit Y, Costagliola D, Autran B, Katlama C; ULTRASTOP Study Group.

AIDS. 2016 Mar 13;30(5):761-9. doi: 10.1097/QAD.0000000000000987.


Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.

Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, Choquet S, Heudel PE, Leblond V, Gabarre J, Valantin MA, Solas C, Guihot A, Carcelain G, Autran B, Katlama C, Quéro L.

Ann Oncol. 2016 Mar;27(3):397-408. doi: 10.1093/annonc/mdv606. Epub 2015 Dec 17. Review.


Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country.

Bourgarit A, Baron G, Breton G, Tattevin P, Katlama C, Allavena C, Campa P, Ravaud P, Lortholary O, Carcelain G; IGRAVIH Study Group.

Ann Am Thorac Soc. 2015 Aug;12(8):1138-45. doi: 10.1513/AnnalsATS.201412-600OC. Erratum in: Ann Am Thorac Soc. 2016 Apr;13(4):576.


Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.

Guihot A, Dentone C, Assoumou L, Parizot C, Calin R, Seang S, Soulié C, Marcelin AG, Calvez V, Autran B, Katlama C, Costagliola D, Carcelain G.

AIDS. 2016 Jan;30(2):327-30. doi: 10.1097/QAD.0000000000000815.


Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.

Hattab S, Guiguet M, Carcelain G, Fourati S, Guihot A, Autran B, Caby F, Marcelin AG, Costagliola D, Katlama C.

HIV Med. 2015 Oct;16(9):553-62. doi: 10.1111/hiv.12257. Epub 2015 May 6.


Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project.

Leibowitch J, Mathez D, de Truchis P, Ledu D, Melchior JC, Carcelain G, Izopet J, Perronne C, David JR.

FASEB J. 2015 Jun;29(6):2223-34. doi: 10.1096/fj.14-260315. Epub 2015 Apr 1.


Interferon-γ release assay vs. tuberculin skin test for tuberculosis screening in exposed healthcare workers: a longitudinal multicenter comparative study.

Lucet JC, Abiteboul D, Estellat C, Roy C, Chollet-Martin S, Tubach F, Carcelain G; QUANTIPS Study Group.

Infect Control Hosp Epidemiol. 2015 May;36(5):569-74. doi: 10.1017/ice.2015.19. Epub 2015 Feb 16.


Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure.

Calin R, Fourati S, Schneider L, Gautheret-Dejean A, Lambert-Niclot S, Wirden M, Carcelain G, Katlama C, Marcelin AG, Tubiana R.

J Antimicrob Chemother. 2015 Jan;70(1):317-9. doi: 10.1093/jac/dku370. Epub 2014 Sep 19. No abstract available.


Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.

Deback C, Burrel S, Varnous S, Carcelain G, Conan F, Aït-Arkoub Z, Autran B, Gandjbakhch I, Agut H, Boutolleau D.

Antivir Ther. 2015;20(2):249-54. doi: 10.3851/IMP2818. Epub 2014 Jun 25. Review.


Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment.

Campillo-Gimenez L, Casulli S, Dudoit Y, Seang S, Carcelain G, Lambert-Niclot S, Appay V, Autran B, Tubiana R, Elbim C.

J Allergy Clin Immunol. 2014 Nov;134(5):1142-52.e5. doi: 10.1016/j.jaci.2014.05.040. Epub 2014 Jul 16.


Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients.

Régent A, Autran B, Carcelain G, Cheynier R, Terrier B, Charmeteau-De Muylder B, Krivitzky A, Oksenhendler E, Costedoat-Chalumeau N, Hubert P, Lortholary O, Dupin N, Debré P, Guillevin L, Mouthon L; French Idiopathic CD4 T Lymphocytopenia Study Group.

Medicine (Baltimore). 2014 Mar;93(2):61-72. doi: 10.1097/MD.0000000000000017.


Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection.

Guihot A, Luyt CE, Parrot A, Rousset D, Cavaillon JM, Boutolleau D, Fitting C, Pajanirassa P, Mallet A, Fartoukh M, Agut H, Musset L, Zoorob R, Kirilovksy A, Combadière B, van der Werf S, Autran B, Carcelain G; FluBAL Study Group.

Am J Respir Crit Care Med. 2014 May 15;189(10):1240-9. doi: 10.1164/rccm.201311-2071OC.


Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.

Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, Caby F, Marcelin AG, Autran B, Costagliola D, Katlama C.

BMC Infect Dis. 2014 Mar 4;14:122. doi: 10.1186/1471-2334-14-122.


Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments.

Fourati S, Lambert-Niclot S, Soulie C, Wirden M, Malet I, Valantin MA, Tubiana R, Simon A, Katlama C, Carcelain G, Calvez V, Marcelin AG.

AIDS. 2014 Feb 20;28(4):487-91. doi: 10.1097/QAD.0000000000000182.


Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.

Fourati S, Flandre P, Calin R, Carcelain G, Soulie C, Lambert-Niclot S, Maiga A, Ait-Arkoub Z, Tubiana R, Valantin MA, Autran B, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2014 Mar;69(3):753-6. doi: 10.1093/jac/dkt428. Epub 2013 Nov 1.


Recalcitrant pseudotumoral anogenital herpes simplex virus type 2 in HIV-infected patients: evidence for predominant B-lymphoplasmocytic infiltration and immunomodulators as effective therapeutic strategy.

Sbidian E, Battistella M, Legoff J, Lafaurie M, Bézier M, Agbalika F, Simon F, Bouscarat F, Cayuela JM, Carcelain G, Houhou N, Bagot M, Molina JM, Janier M, Bachelez H.

Clin Infect Dis. 2013 Dec;57(11):1648-55. doi: 10.1093/cid/cit592. Epub 2013 Sep 24.


Immune interventions in HIV infection.

Carcelain G, Autran B.

Immunol Rev. 2013 Jul;254(1):355-71. doi: 10.1111/imr.12083. Review.


CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity.

Lescure FX, Moulignier A, Savatovsky J, Amiel C, Carcelain G, Molina JM, Gallien S, Pacanovski J, Pialoux G, Adle-Biassette H, Gray F.

Clin Infect Dis. 2013 Jul;57(1):101-8. doi: 10.1093/cid/cit175. Epub 2013 Mar 20.


Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIV-infected patients.

Descours B, Lambert-Niclot S, Mory B, Samri A, Charlotte F, Peytavin G, Tubiana R, Papagno L, Bacchus C, Lecardonnel F, Katlama C, Autran B, Marcelin AG, Valantin MA, Carcelain G; DECAMUNE and ORVACS Study Groups.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):255-9. doi: 10.1097/QAI.0b013e318282537f.


Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.

Soulié C, Charpentier C, Flandre P, Nino C, Carcelain G, Simon A, Katlama C, Landman R, Brun-Vézinet F, Descamps D, Calvez V, Marcelin AG.

J Med Virol. 2012 Dec;84(12):1853-6. doi: 10.1002/jmv.23362.


HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs.

Fourati S, Lambert-Niclot S, Soulie C, Malet I, Valantin MA, Descours B, Ait-Arkoub Z, Mory B, Carcelain G, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2012 Oct;67(10):2323-6. doi: 10.1093/jac/dks219. Epub 2012 Jun 11.


Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells.

Descours B, Avettand-Fenoel V, Blanc C, Samri A, Mélard A, Supervie V, Theodorou I, Carcelain G, Rouzioux C, Autran B; ALT ANRS CO15 Study Group.

Clin Infect Dis. 2012 May;54(10):1495-503. doi: 10.1093/cid/cis188. Epub 2012 Mar 22.


Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.

Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, Flipo RM, Goupille P, Allez M, Salmon D, Emilie D, Carcelain G, Ravaud P.

Ann Rheum Dis. 2012 Nov;71(11):1783-90. doi: 10.1136/annrheumdis-2011-200408. Epub 2012 Jan 17.


QuantiFERON-TB gold cut-off value: implications for the management of tuberculosis-related ocular inflammation.

Gineys R, Bodaghi B, Carcelain G, Cassoux N, Boutin LTH, Amoura Z, Lehoang P, Trad S.

Am J Ophthalmol. 2011 Sep;152(3):433-440.e1. doi: 10.1016/j.ajo.2011.02.006. Epub 2011 Jun 8.


[Enhancing immune restoration in human immunodeficiency virus infection].

Sahali S, Carcelain G, Goujard C, Delfraissy JF, Ghosn J.

Rev Med Interne. 2011 Jul;32(7):425-31. doi: 10.1016/j.revmed.2011.02.011. Epub 2011 Mar 26. French.


HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis.

Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, Guihot A, Boufassa F, Zaunders J, Iguertsira M, Bailey M, Gorochov G, Duvivier C, Carcelain G, Kelleher AD, Simon A, Meyer L, Costagliola D, Deeks SG, Lambotte O, Autran B, Hunt PW, Katlama C, Appay V.

Blood. 2011 May 12;117(19):5142-51. doi: 10.1182/blood-2011-01-331306. Epub 2011 Mar 24.


Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: beware of immune reconstitution inflammatory syndrome.

Rivoisy C, Amrouche L, Carcelain G, Séréni D, Bourgarit A.

Joint Bone Spine. 2011 May;78(3):312-5. doi: 10.1016/j.jbspin.2011.01.003. Epub 2011 Feb 22. Review.


Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus.

Guihot A, Bourgarit A, Carcelain G, Autran B.

Trends Immunol. 2011 Mar;32(3):131-7. doi: 10.1016/ Epub 2011 Feb 12. Review.


The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study.

Lanoy E, Spano JP, Bonnet F, Guiguet M, Boué F, Cadranel J, Carcelain G, Couderc LJ, Frange P, Girard PM, Oksenhendler E, Poizot-Martin I, Semaille C, Agut H, Katlama C, Costagliola D; ONCOVIH study group.

Int J Cancer. 2011 Jul 15;129(2):467-75. doi: 10.1002/ijc.25903. Epub 2011 Apr 27.


Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients.

Canestri A, Krivine A, Assoumou L, Le Corre M, Rozenberg F, Marcelin AG, Schneider L, Samri A, Carcelain G, Autran B, Katlama C, Guihot A.

AIDS. 2010 Nov 27;24(18):2887-9. doi: 10.1097/QAD.0b013e3283402bc1.


Fetal death as a result of placental immune reconstitution inflammatory syndrome.

Caby F, Lemercier D, Coulomb A, Grigorescu R, Paris L, Touafek F, Carcelain G, Canestri A, Pauchard M, Katlama C, Dommergues M, Tubiana R.

J Infect. 2010 Jul;61(2):185-8. doi: 10.1016/j.jinf.2010.03.026. Epub 2010 Mar 31.


Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy.

Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, Assoumou L, Goncalves E, Bricaire F, Costagliola D, Calvez V, Rouzioux C, Autran B, Katlama C, Carcelain G; ALT-ANRS CO-15 study group; DECAMUNE study group.

AIDS. 2010 Feb 20;24(4):614-7. doi: 10.1097/QAD.0b013e32833556f3.


Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells.

Bourgarit A, Carcelain G, Samri A, Parizot C, Lafaurie M, Abgrall S, Delcey V, Vicaut E, Sereni D, Autran B; PARADOX Study Group.

J Immunol. 2009 Sep 15;183(6):3915-23. doi: 10.4049/jimmunol.0804020.


CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3.

Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X; FHDH-ANRS CO4 Epidemiology Group.

Antivir Ther. 2009;14(3):451-7.


Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies.

Miceli-Richard C, Gestermann N, Amiel C, Sellam J, Ittah M, Pavy S, Urrutia A, Girauld I, Carcelain G, Venet A, Mariette X.

Arthritis Res Ther. 2009;11(3):R77. doi: 10.1186/ar2708. Epub 2009 May 26.


Non-sexually related acute genital ulcers in 13 pubertal girls: a clinical and microbiological study.

Farhi D, Wendling J, Molinari E, Raynal J, Carcelain G, Morand P, Avril MF, Francès C, Rozenberg F, Pelisse M, Dupin N.

Arch Dermatol. 2009 Jan;145(1):38-45. doi: 10.1001/archdermatol.2008.519.


T cells subtypes in a patient with interferon-alpha induced sarcoidosis.

Monsuez JJ, Carcelain G, Charniot JC, Barrière J, Duclos-Vallée JC, Parent F, Autran B.

Am J Med Sci. 2009 Jan;337(1):60-2. doi: 10.1097/01.MAJ.0000308932.93221.68.


Increased surface receptor Fas (CD95) levels on CD4+ lymphocytes in patients with primary intestinal lymphangiectasia.

Vignes S, Carcelain G.

Scand J Gastroenterol. 2009;44(2):252-6. doi: 10.1080/00365520802321220.


Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation.

Sacre K, Nguyen S, Deback C, Carcelain G, Vernant JP, Leblond V, Autran B, Dhedin N.

J Virol. 2008 Oct;82(20):10143-52. doi: 10.1128/JVI.00688-08. Epub 2008 Aug 6.


Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.

Derache A, Maiga AI, Traore O, Akonde A, Cisse M, Jarrousse B, Koita V, Diarra B, Carcelain G, Barin F, Pizzocolo C, Pizarro L, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2008 Sep;62(3):456-63. doi: 10.1093/jac/dkn234. Epub 2008 Jun 13.


Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients.

Simonney N, Dewulf G, Herrmann JL, Gutierrez MC, Vicaut E, Boutron C, Leportier M, Lafaurie M, Abgrall S, Sereni D, Autran B, Carcelain G, Bourgarit A, Lagrange PH.

Tuberculosis (Edinb). 2008 Sep;88(5):453-61. doi: 10.1016/ Epub 2008 May 21.


Comparison of two genotypic algorithms to determine HIV-1 tropism.

Soulié C, Derache A, Aimé C, Marcelin AG, Carcelain G, Simon A, Katlama C, Calvez V.

HIV Med. 2008 Jan;9(1):1-5. doi: 10.1111/j.1468-1293.2008.00518.x.


HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.

Marcelin AG, Jarrousse B, Derache A, Ba M, Dakouo ML, Doumbia A, Haidara I, Maïga A, Carcelain G, Peytavin G, Katlama C, Calvez V.

AIDS. 2007 Nov 12;21(17):2341-3.


Supplemental Content

Loading ...
Support Center